Findings from Denosumab (Prolia (R)) Post-marketing Safety Surveillance for Atypical Femoral Fracture, Osteonecrosis of the Jaw, Severe Symptomatic Hypocalcemia, and Anaphylaxis
Author(s):
Geller, M.; Wagman, R.B.; Ho, P.R.; Siddhanti, S.; Stehman-Breen, C.; Watts, N.B.; Papapoulos, S.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-02-28
Language
English
Is part of
Journal of Bone and Mineral Research (2014), Vol. 29, p. S113-S113
